Camrelizumab in Combination With Neoadjuvant Chemotherapy

DRUG2 trials

Sponsors

Sun Yat-sen University

Conditions

OsteosarcomaSoft Tissue Sarcoma

Phase 2

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Sun Yat-sen UniversityOsteosarcoma

Start: 2019-12-26End: 2023-09-16Target: 75Updated: 2020-03-04

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Sun Yat-sen UniversitySoft Tissue Sarcoma

Start: 2020-10-19End: 2024-03-19Target: 62Updated: 2020-10-28

Related Papers

Neoadjuvant treatment with camrelizumab in combination with doxorubicin and ifosfamide: A phase II clinical study of high-risk soft tissue sarcoma.

Journal of Clinical Oncology2024-06-01

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate as neoadjuvant therapy for osteosarcoma: A single-arm, exploratory phase II trial.

Journal of Clinical Oncology2023-06-01